On September 3, 2025, NVIDIA announced raising $150 million in a Series D funding round, bringing its total funding to $517 million and its market cap to more than $1 billion. The company uses an artificial intelligence platform to analyze millions of plant compounds and predict their biological effects and link them to complex diseases, accelerating discovery and reducing costs compared to traditional methods. The platform has produced more than 12 drug candidates, including ENV-294, which is in clinical trials for atopic dermatitis and asthma. The company has also signed an agreement with Sanofi to advance the clinical adoption of these discoveries. Detailed performance indicators of the effectiveness of the algorithms or the range of data used have not yet been disclosed.
Nvidia (AI drug discovery platform) raises $150 million.
